Drug Profile


Alternative Names: PRC 4016

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pronova BioPharma
  • Class Antihyperlipidaemics; Omega 3 fatty acids; Unsaturated fatty acids
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dyslipidaemias; Hypertriglyceridaemia
  • Phase I Hypercholesterolaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in United Kingdom (PO, Capsule)
  • 01 Aug 2015 Pronova BioPharma completes a phase I trial in healthy volunteers in United Kingdom (NCT02364635)
  • 25 May 2015 Safety, efficacy and pharmacodynamics data from a phase II trial in Hypertriglyceridaemia released by BASF
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top